Opinion|Videos|August 20, 2026
Real-World Experience and Integrating FLAURA2, TOP, and FLAME Into Practice
Author(s)Sandip Patel, MD, Amy Cummings, MD, PhD,
The faculty discuss how these data are applied in practice and where real-world experience sits in the evidence hierarchy.
Advertisement
The faculty discuss how these data are applied in practice and where real-world experience sits in the evidence hierarchy. Synthesizing FLAURA2, TOP, and FLAME, the faculty conclude that patients with high-risk disease based on the burden (i.e. brain metastases, painful bone metastases, high tumor shedding) or TP53 co-mutation should prompt intensification.
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.
Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, being evaluated in pancreatic ductal adenocarcinoma.
ctDNA clearance and MRD status may help identify which patients with resectable NSCLC get the greatest benefit from perioperative immunotherapy.
PLN-101095 earned an FDA fast track designation in combination with pembrolizumab for solid tumors resistant to immune checkpoint inhibitors.
Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.
Harold P. Freeman, MD, pioneer of patient navigation and cancer disparities research, has died at 93. He spent decades bridging gaps in cancer care access.
Intismeran autogene plus pembrolizumab improved recurrence-free survival and distant metastasis–free survival in resected stage IIB to IV melanoma.
Advertisement
Advertisement
Trending on OncLive
1
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
2
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
3
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
4
Dr Skoulidis on First-Line Divarasib Plus Pembrolizumab in KRAS G12C+ NSCLC
5